Syncona shares rise after Beacon Therapeutics reports positive trial data
Syncona gained 5.8% in European morning trading Monday after portfolio company Beacon Therapeutics said a gene therapy for a blindness-causing disease achieved positive results in a pivotal study.
Shares in life-sciences investor Syncona rose after portfolio company Beacon Therapeutics reported positive results from a pivotal study of a gene therapy for a disease that causes blindness. 8% in European morning trading Monday, taking their year-to-date…